Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 3/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | ACSS2 | Q9NR19 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.32 |
| ▸ | PER2 | O15055 | 2/20 | 0.31 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.31 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12000450 | 0.92 | P2RX3 (0.38) | TLR8POLBALDH1A1TSHRPER2 | |
| SCHEMBL2748577 | 0.90 | ALOX5 (0.35) | ACSS2KDM4E | |
| SCHEMBL1668035 | 0.89 | PPARG (0.34) | ACSS2SOS1PER2 | |
| SCHEMBL2332123 | 0.88 | ACSS2 (0.34) | ACSS2LMNAPER2 | |
| SCHEMBL2748869 | 0.88 | PER2 (0.41) | KCNH2ACSS2TP53PER2 | |
| SCHEMBL1666066 | 0.87 | MTNR1A (0.37) | KCNH2ACSS2 | |
| SCHEMBL1665776 | 0.86 | S1PR1 (0.39) | ACSS2SOS1KDM4E | |
| SCHEMBL5062964 | 0.86 | CYP11B2 (0.40) | KCNH2ACSS2LMNA | |
| SCHEMBL1665637 | 0.86 | LMNA (0.42) | POLBALDH1A1TSHRLMNAMAPT | |
| SCHEMBL2750491 | 0.86 | MEN1 (0.34) | LMNAPER2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178533-B2 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2012-05-15 | — | — | US | claimed |
| EP-1912966-A2 | 2-OXO-1-PYRROLIDINE DERIVATIVES AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM | UCB, S.A. (BE) | 2008-04-23 | — | — | EP | claimed |
| EP-1891042-A2 | 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM | UCB Pharma, S.A. (BE) | 2008-02-27 | — | — | EP | claimed |
| WO-2006128693-A2 | 2 -OXO-I -PYRROLIDINE DERIVATIVES/ PROCESSES FOR PREPARING THEM AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM | UCB PHARMA, S.A. (BE) | 2006-12-07 | — | — | WO | claimed |
| WO-2006128692-A2 | 2-OXO-1-PYRROLIDINE DERIVATIVES AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM | UCB PHARMA, S.A. (BE) | 2006-12-07 | — | — | WO | claimed |
| EP-2968220-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | Agenebio, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2968257-A1 | METHODS AND COMPOSITONS FOR IMPROVING COGNITIVE FUNCTION | The Johns Hopkins University (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2968237-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | The Johns Hopkins University (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2919788-A1 | METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA | The Johns Hopkins University (US) | 2015-09-23 | — | — | EP | disclosed |
| WO-2014144663-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014144546-A1 | METHODS AND COMPOSITONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014144801-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | AGENEBIO INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20120196866-A1 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses | UCB PHARMA, S.A. (BE) | 2012-08-02 | — | — | US | disclosed |
| WO-2011100373-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-08-18 | — | — | WO | disclosed |
| EP-2308867-A2 | 2-oxo-1-pyrrolidine deriatives, processes for preparing them and their uses | UCB Pharma S.A. (BE) | 2011-04-13 | — | — | EP | disclosed |
| EP-2308870-A2 | 2-oxo-1-pyrrolidine deriatives, processes for preparing them and their uses | UCB Pharma S.A. (BE) | 2011-04-13 | — | — | EP | disclosed |
| EP-1912966-A2 | 2-OXO-1-PYRROLIDINE DERIVATIVES AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM | UCB, S.A. (BE) | 2008-04-23 | — | — | EP | disclosed |
| EP-1891042-A2 | 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM | UCB Pharma, S.A. (BE) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006128693-A2 | 2 -OXO-I -PYRROLIDINE DERIVATIVES/ PROCESSES FOR PREPARING THEM AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM | UCB PHARMA, S.A. (BE) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006128692-A2 | 2-OXO-1-PYRROLIDINE DERIVATIVES AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM | UCB PHARMA, S.A. (BE) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196866-A1 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses | CYP3A4, CYP1B1, CYP2D6 | TLR8 3822/4885POLB 442/4885KCNH2 2291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.